Nootropic
Hydrafinil
SaveA fluorenol compound (9-fluorenol) structurally unrelated to modafinil but sharing wakefulness-promoting properties. Not approved as a pharmaceutical anywhere.
Quick verdict
Limited animal data suggests eugeroic properties. No human clinical trials; it remains an unregulated research chemical.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
A single Cephalon patent application reported greater wakefulness-promoting potency than modafinil in rodents, but the compound was never developed clinically.
Benefits
- Reported eugeroic activity in rodent models
- Anecdotal reports of clean wakefulness
Dosage notes
No validated dosing. Self-experimenters report 50–150 mg, but this is not evidence-based.
Side effects
- Headache (anecdotal)
- Insomnia
- Unknown long-term risks
Who should be cautious
No human safety data. Unknown drug interactions. Not approved for any indication.
What this page cannot tell you
Claims of superiority to modafinil are based on a single rodent study in a patent application, not peer-reviewed research.
Leaderboard scores
- Energy40
- Focus35
Write a review
Sign in to write a review.